SyVento BioTech is proud to announce that, as of 31 July 2025, the company has officially obtained the Manufacturer/Importer Authorisation (MIA) — a vital regulatory certification that enables the manufacturing and importation of sterile and biological investigational medicinal products in full compliance with Good Manufacturing Practice (GMP) standards.
This certification marks a major milestone for SyVento BioTech and represents a first-of-its-kind achievement in Poland. With the MIA in place, SyVento BioTech is now the first company in Poland authorised to manufacture and release investigational medicinal products based on mRNA and lipid nanoparticles (LNPs) — all under one roof and ready for use in clinical trials.
“We’re incredibly proud to contribute to the advancement of next-generation therapies and to support our partners in bringing innovative medicines to patients. This authorisation not only reinforces our commitment to quality, innovation, and compliance, but also strengthens our position as a trusted partner in the biotechnology and pharmaceutical sectors.” — said Dominik Lipka, PhD Eng., CTO of SyVento BioTech.
With this certification, SyVento BioTech is now fully equipped to expand its capabilities, accelerate development pipelines, and deepen collaborations across the biotech field — from early-stage innovators to global pharmaceutical leaders.
